SB 1377, the Voluntary Portable Benefit Plan Act, allows businesses to voluntarily contribute to portable benefit plans for independent contractors. These plans, administered by third-party providers chosen by the contractor, cover health, disability, unemployment, life insurance, and retirement benefits. Contributions can be made directly by the business or by withholding a portion of the contractor’s pay, but only with a clear written opt-in agreement and the ability to opt out at any time. The bill amends Tennessee law to ensure these contributions cannot be used to determine a worker’s employment classification as an employee or independent contractor.
SB 1290 permanently removes a temporary expiration date for a law that excludes certain testing equipment from being classified as drug paraphernalia. Specifically, it makes permanent the exclusion of equipment used to test for synthetic opioids (like fentanyl) unless the equipment is used to commit a drug crime. This change directly affects harm reduction organizations, public health workers, and law enforcement using such tools for legitimate testing purposes. The bill amends Tennessee Code Annotated Section 39-17-402 by deleting the prior repeal date of July 1, 2025. The law is now permanent and took effect April 3, 2025.
SB 1305 extends Tennessee's CoverKids health insurance program for children by changing its expiration date from June 30, 2025, to June 30, 2030. This bill directly affects low-income children in Tennessee who qualify for the CoverKids program, ensuring continued access to health coverage. The key mechanism is amending Tennessee Code Annotated Section 71-3-1113 to update the program's termination date. The bill was signed into law on April 3, 2025, and became effective April 8, 2025.
HB 62 authorizes Tennessee athletic trainers to use dry needling for preventing, treating, and rehabilitating athletic injuries, directly affecting licensed athletic trainers in the state. The bill requires the Board of Athletic Trainers to establish minimum competency standards that practitioners must demonstrate to safely perform dry needling. It clarifies that this practice does not constitute acupuncture under existing law. The policy change expands athletic trainers' scope of practice with specific safety safeguards, effective March 28, 2025.
SB 569 prevents pharmacies from charging administrative fees for hormonal contraceptives when a patient's insurance covers the cost and includes pharmacy benefits. It directly affects insured patients seeking hormonal contraceptives and pharmacists who previously might have charged such fees. The bill amends Tennessee law to remove language allowing pharmacies to require these fees, ensuring patients covered by insurance do not face additional costs. The law takes effect July 1, 2025, and applies to all pharmacies in Tennessee.
HB 1157, the "Restore Trust in Public Health Messaging Act," requires Tennessee's Department of Health, local health departments, and state executive branch to ensure all public communications about FDA-regulated products (like medications) accurately reflect the FDA-approved or FDA-authorized labels. It prohibits promoting information that conflicts with these labels, including general product categories unless universally true or properly qualified. The law mandates an internal compliance review by July 2025, annual reporting to state officials starting in 2026, and a complaint process for violations with potential penalties. This directly affects state health agencies' public messaging about medical products, aiming to align communications with federal FDA standards.
HB 1169 requires Tennessee's Council on Children's Mental Health to submit annual reports starting June 30, 2026, detailing the statewide mental health system for children. The reports must cover current services (including state/federal programs), gaps in care, and recommendations for better coordination between agencies. The council must gather input from relevant departments (mental health, education, health, etc.) to create a comprehensive overview. These reports will be shared with the governor, legislative leaders, and agency heads. The bill, effective March 28, 2025, updates existing law to ensure regular oversight of children's mental health services.
HB 498 creates an advisory task force to review and recommend annual adjustments to state reimbursement rates paid to healthcare agencies in Tennessee. The task force, composed of 6 appointed members (3 by each legislative chamber, representing different health professions) and ex-officio agency representatives, will focus on ensuring rates cover agency costs, staff salaries, and administrative needs. It must submit annual recommendations by August 1, starting in 2026, to state officials and legislative committees, considering factors like provider costs, staff compensation, and workforce shortages. The bill directly affects healthcare agencies providing state-funded services, aiming to make reimbursement rates more adequate without changing existing funding levels.
SB 152 allows patients with severe chronic diseases or terminal illnesses to access investigational stem cell treatments (adult stem cell therapies still in clinical trials and not yet FDA-approved) after their doctors confirm other FDA-approved treatments aren't viable. It requires Tennessee’s health commissioner to create rules listing qualifying medical conditions and mandates doctors to document that all standard treatments were considered before recommending these experimental therapies. The bill also protects physicians from license penalties for following these guidelines and prohibits government interference with patient access. This directly affects patients with qualifying conditions and their treating physicians in Tennessee.
HJR 80 designates May 2025 as "National Hypertension Month" in Tennessee. The resolution urges healthcare providers, insurers, and TennCare to promote hypertension awareness and support coverage for renal denervation therapies, which treat resistant hypertension. It advocates for policy changes to improve access to innovative treatments but does not create new legal requirements. As a symbolic resolution, it encourages state-level action without mandating specific outcomes.
